Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Updates Upbeat Revenue Guidance

Albany, New York (09/23/2014) – A specialty Pharmaceutical company, Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has provided an upbeat updated revenue outlook for the current year that has the potential to lift the sentiments of investors. The stock would be worth watching on Tuesday.

Outlook

The Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has reiterated that it would expect to generate revenue of about $105 million in the current year of 2014, its statement revealed. It said that it was focusing its efforts on executing its current tactics to optimize its shareholders value.

The revenue outlook suggests a big jump from $12.02 million achieved in the last year. On average, Street analysts’ estimate the pharmaceutical company to deliver revenue of $104.44 million.

Significantly, Supernus Pharmaceuticals Inc (NASDAQ:SUPN) disclosed that it was not planning to raise any additional capital to attain profitability. The company expressed its confidence of achieving profitability in the current year itself.

The company also reiterated that it was on track to achieve breakeven cash flow by the year end and that it hoped to close the year with a cash balance between $75 and $85 million.

Intellectual Property Position

The company said that its portfolio of epilepsy products, Trokendi XR and Oxtellar XR, which were launched in the previous year successfully, were in the early stage of growth. These products have potential to deliver sales of $400 - $500 million. It would continue its efforts to strengthen its intellectual property position on these two products with four patents. It expects expiry for these patents not before 2027. The company also indicated that it has taken steps to ensure that the products were fully covered by patent protections full scope for which they were entitled.

Pipeline Development

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) said that it has demonstrated significant progress in the development of its product pipeline with the recent Food and Drug Administration or the FDA’s fast track designation of its SPN-810 apart from the selection of its SPN-812. It said that it has finalized major part of work on the development, as well as, manufacturing of the active drug substance.

About the Author

Sally joined the US Markets Daily News Team in April 2011 as a Multimedia Journalist.

Leave A Response